Do analysts rate GNPX or KALA?

KALA BIO has a consensus target price of $75.00, suggesting a potential upside of 14,278.83%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has better valuation and earnings, GNPX or KALA?

Genprex is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$133.36 N/A KALA BIO N/A N/A -$26.98M -$31.96 N/A

Is GNPX or KALA more profitable?

Genprex's return on equity of -163.12% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -163.12% -128.98% KALA BIO N/A -222.35% -70.23%

Do analysts rate FBLG or GNPX?

FibroBiologics currently has a consensus target price of $73.00, indicating a potential upside of 5,004.90%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities analysts clearly believe FibroBiologics is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, FBLG or GNPX?

FibroBiologics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$5.19 N/A Genprex N/A N/A -$16.23M -$133.36 N/A

Is FBLG or GNPX more profitable?

Genprex's return on equity of -163.12% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% Genprex N/A -163.12% -128.98%

Do analysts rate GNPX or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, GNPX or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$133.36 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is GNPX or LNAI more profitable?

Genprex's return on equity of -163.12% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -163.12% -128.98% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts prefer INAB or GNPX?

IN8bio presently has a consensus target price of $4.00, suggesting a potential upside of 296.04%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, INAB or GNPX?

IN8bio is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.62 N/A Genprex N/A N/A -$16.23M -$133.36 N/A

Is INAB or GNPX more profitable?

IN8bio's return on equity of -91.18% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Genprex N/A -163.12% -128.98%

Do analysts prefer GNPX or VTGN?

VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 311.97%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Genprex (GNPX) Competitors

$3.41 +0.10 (+3.02%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$3.40 -0.01 (-0.29%)

As of 06:45 AM Eastern

Compare

GNPX vs. KALA, FBLG, LNAI, INAB, and VTGN

Should you buy Genprex stock or one of its competitors? Genprex's main competitors and comparable companies include KALA BIO (KALA), FibroBiologics (FBLG), Lunai Bioworks (LNAI), IN8bio (INAB), and VistaGen Therapeutics (VTGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genprex compare to KALA BIO?

Genprex (NASDAQ:GNPX) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, KALA BIO had 1 more articles in the media than Genprex. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for Genprex. Genprex's average media sentiment score of 1.87 beat KALA BIO's score of 0.44 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Very Positive
KALA BIO	Neutral

Genprex has a beta of -0.94, indicating that its share price is 194% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.28, indicating that its share price is 328% less volatile than the broader market.

KALA BIO has a consensus target price of $75.00, suggesting a potential upside of 14,278.83%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Genprex is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A

Genprex's return on equity of -163.12% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
KALA BIO	N/A	-222.35%	-70.23%

14.1% of Genprex shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 0.3% of Genprex shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

KALA BIO beats Genprex on 8 of the 12 factors compared between the two stocks.

How does Genprex compare to FibroBiologics?

FibroBiologics (NASDAQ:FBLG) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

FibroBiologics currently has a consensus target price of $73.00, indicating a potential upside of 5,004.90%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities analysts clearly believe FibroBiologics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, FibroBiologics had 2 more articles in the media than Genprex. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for Genprex. Genprex's average media sentiment score of 1.87 beat FibroBiologics' score of 0.62 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
FibroBiologics	Positive
Genprex	Very Positive

FibroBiologics has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Genprex has a beta of -0.94, suggesting that its share price is 194% less volatile than the broader market.

Genprex's return on equity of -163.12% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
Genprex	N/A	-163.12%	-128.98%

14.1% of Genprex shares are owned by institutional investors. 7.3% of FibroBiologics shares are owned by company insiders. Comparatively, 0.3% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

FibroBiologics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

Summary

FibroBiologics beats Genprex on 7 of the 13 factors compared between the two stocks.

How does Genprex compare to Lunai Bioworks?

Genprex (NASDAQ:GNPX) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Lunai Bioworks had 1 more articles in the media than Genprex. MarketBeat recorded 2 mentions for Lunai Bioworks and 1 mentions for Genprex. Genprex's average media sentiment score of 1.87 beat Lunai Bioworks' score of 0.93 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Very Positive
Lunai Bioworks	Positive

Lunai Bioworks is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

Genprex's return on equity of -163.12% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genprex has a beta of -0.94, meaning that its share price is 194% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

14.1% of Genprex shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 0.3% of Genprex shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Genprex and Lunai Bioworks tied by winning 5 of the 10 factors compared between the two stocks.

How does Genprex compare to IN8bio?

IN8bio (NASDAQ:INAB) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

IN8bio presently has a consensus target price of $4.00, suggesting a potential upside of 296.04%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IN8bio's return on equity of -91.18% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Genprex	N/A	-163.12%	-128.98%

92.1% of IN8bio shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 0.3% of Genprex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IN8bio is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

In the previous week, IN8bio had 3 more articles in the media than Genprex. MarketBeat recorded 4 mentions for IN8bio and 1 mentions for Genprex. Genprex's average media sentiment score of 1.87 beat IN8bio's score of 0.57 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Genprex	Very Positive

IN8bio has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Genprex has a beta of -0.94, indicating that its stock price is 194% less volatile than the broader market.

Summary

IN8bio beats Genprex on 10 of the 13 factors compared between the two stocks.

How does Genprex compare to VistaGen Therapeutics?

Genprex (NASDAQ:GNPX) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Genprex has higher earnings, but lower revenue than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
VistaGen Therapeutics	$1.27M	8.06	-$69.68M	-$1.66	N/A

Genprex has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

Genprex has a beta of -0.94, indicating that its share price is 194% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 311.97%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, VistaGen Therapeutics had 2 more articles in the media than Genprex. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 1 mentions for Genprex. Genprex's average media sentiment score of 1.87 beat VistaGen Therapeutics' score of 0.63 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Very Positive
VistaGen Therapeutics	Positive

14.1% of Genprex shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 0.3% of Genprex shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

VistaGen Therapeutics beats Genprex on 10 of the 14 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNPX vs. The Competition

Export

Metric	Genprex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.71M	$3.84B	$7.22B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	-0.03	14.33	273.86	25.33
Price / Sales	N/A	1,412.17	643.61	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	0.06	15.13	10.33	6.24
Net Income	-$16.23M	-$22.78M	$3.49B	$358.55M
7 Day Performance	1.79%	-2.54%	-0.84%	-1.20%
1 Month Performance	-23.71%	-2.87%	-1.37%	-4.26%
1 Year Performance	-98.67%	37.93%	21.13%	5.47%

Genprex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNPX Genprex	0.547 of 5 stars	$3.41 +3.0%	N/A	-98.9%	$2.71M	N/A	N/A	20
KALA KALA BIO	1.838 of 5 stars	$0.58 +2.7%	$912.50 +157,772.0%	-99.9%	$11.18M	N/A	N/A	30	Short Interest Increase Gap Up
FBLG FibroBiologics	2.2186 of 5 stars	$1.67 -3.6%	$73.00 +4,276.5%	-86.5%	$11.09M	N/A	N/A	10
LNAI Lunai Bioworks	0.3177 of 5 stars	$2.35 -3.3%	N/A	N/A	$10.67M	N/A	N/A	20	News Coverage Gap Up
INAB IN8bio	3.4896 of 5 stars	$1.07 -3.2%	$4.00 +275.6%	-50.0%	$10.51M	N/A	N/A	20	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNPX) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genprex (GNPX) Competitors

GNPX vs. KALA, FBLG, LNAI, INAB, and VTGN

How does Genprex compare to KALA BIO?

Summary

How does Genprex compare to FibroBiologics?

Summary

How does Genprex compare to Lunai Bioworks?

Summary

How does Genprex compare to IN8bio?

Summary

How does Genprex compare to VistaGen Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genprex (GNPX) Competitors

GNPX vs. KALA, FBLG, LNAI, INAB, and VTGN

How does Genprex compare to KALA BIO?

Does the media prefer GNPX or KALA?

Which has more volatility and risk, GNPX or KALA?

Do analysts rate GNPX or KALA?

Which has better valuation and earnings, GNPX or KALA?

Is GNPX or KALA more profitable?

Do institutionals and insiders have more ownership in GNPX or KALA?

Summary

How does Genprex compare to FibroBiologics?

Do analysts rate FBLG or GNPX?

Does the media refer more to FBLG or GNPX?

Which has more risk & volatility, FBLG or GNPX?

Is FBLG or GNPX more profitable?

Do institutionals & insiders have more ownership in FBLG or GNPX?

Which has better earnings & valuation, FBLG or GNPX?

Summary

How does Genprex compare to Lunai Bioworks?

Does the media refer more to GNPX or LNAI?

Which has higher valuation and earnings, GNPX or LNAI?

Is GNPX or LNAI more profitable?

Do analysts rate GNPX or LNAI?

Which has more risk and volatility, GNPX or LNAI?

Do insiders and institutionals hold more shares of GNPX or LNAI?

Summary

How does Genprex compare to IN8bio?

Do analysts prefer INAB or GNPX?

Is INAB or GNPX more profitable?

Do institutionals & insiders hold more shares of INAB or GNPX?

Which has preferable earnings and valuation, INAB or GNPX?

Does the media refer more to INAB or GNPX?

Which has more risk and volatility, INAB or GNPX?

Summary

How does Genprex compare to VistaGen Therapeutics?

Which has stronger valuation and earnings, GNPX or VTGN?

Is GNPX or VTGN more profitable?

Which has more volatility and risk, GNPX or VTGN?

Do analysts prefer GNPX or VTGN?

Does the media refer more to GNPX or VTGN?

Do institutionals and insiders hold more shares of GNPX or VTGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools